GSK’s New Research Chief Begins Leadership With Expanded Genomics/AI Alliance
Doubles Down On Precision Medicine
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
You may also be interested in...
Daily notebook from the J.P. Morgan Healthcare Conference: Small and mid-size companies take the stage to lay out their guidance for the year, while big pharma is pushed on strategy and business development. Updates from GSK, Mirati, Sarepta, Amgen and US FDA commissioner Robert Califf.
Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.
In this week's podcast edition of Five Must-Know Things: J&J and Roche’s first-half wins and challenges; Alexion’s Ultomiris plans; GSK’s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.